Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
INVESTING WARNING THIS SCAM HAVE NOT COVID-19 pipelines! THIS IS LYING AND FRAUD PUMP AND DUMP
Thx for heads up... buying some 8,80‘s
It is so funny the MMs behave so weird. Take the price down to scare
Nice find Chessmaster. Thank you for posting.
Lk May run today atos anytime it can run news next week fda 10 x more powerful than gild drug. Back to bed keep on watch both may run starting today
True, but when something spikes like that it almost always pulls back about half of the spike on profit taking. That looks like where you’re at now.
GL
There must be a reason it went up to $22 yesterday, that reason is still there!!!
Put alert at around 250 when she hits that price it should run and fast take easy
They're gonna gap it down hard today it looks like. $14 pre market. FOMO could bid it right back up.
Glad I took my fast 60% yesterday. Congrats and good luck to everyone.
NM
damn look at that volume definitely a short squeeze. LMAO 1000% IN weeks.
Go to atos sympathy play to this fda next week and low floater like this the only reason why this went up so much low float atos fda coming soon
* * $ABIO Video Chart 05-28-2020 * *
Link to Video - click here to watch the technical chart video
Nice pop today
Wondering any offering tmrw?
Wow congrats on the beginning of a MOASS Longs, wish I saw it earlier
Are u selling?
Congrats to the folks in before today. WOW!
Hell yeah. Watch for the secondary offering.
Holy crap I’m up over 60% already. I’m about to take it off it will pull back at some point. It’s just plans to test is that correct?
Don’t know where this will end today... but right now this looks like still a buy lol
Wooowzaaaa well done buddy!!!
ABIO 14.50!!!
I caught some @ 10.65 on the dip
$ABIO
Hmmmm,imo down from here at 11,70
What a crazy day - still should get steam in afternoon - $20 target
ABIO $13.50 now that was crazy
Ok, I couldn't help but chase the momo a little. Up over 25% already. Congrats to everyone up massively today.
Now going Crazy
208% now woooowzaaa
Up 180% on the day. Damn, missed that one. LOL. Not chasing it, just fascinated.
Congrats to anyone holding already. Take something off the table.
GL
ABIO 6.70 FROM 7.79
ABIO News Alert: ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
I doubt it for a Coronavirus play or any play! They can’t even get genarco to work and they been working on that for over 11 years! Company’s a debacle in my opinion
Is corona-virus vaccine a big possibility here? I am interested
The Proposed Gencaro Phase 3 Clinical Trial
The PRECISION-AF Phase 3 clinical trial is designed as a double-blind, active-controlled, multicenter, international, adaptive study comparing Gencaro with TOPROL-XL for the prevention of recurrent AF/atrial flutter, or AF/AFL, or all-cause mortality, or ACM, in HF patients. The study will enroll approximately 400 patients at investigative sites in the United States, Europe and Australia. Eligible patients will have LVEF ≥ 0.40 and ≤ 0.55, a recent AF event, and the beta-1 389 arginine homozygous genotype which we believe responds most favorably to Gencaro. The planned trial will use standard significance criteria (p < 0.01 with adjustment for interim analysis) for the primary endpoint and will include an interim analysis after a portion of total patients have been enrolled. The interim analysis is designed to assess safety, validate initial study assumptions and maintain adequate statistical power for the primary endpoint. Subject to securing additional financing, we anticipate initiating PRECISION-AF in the first quarter of 2020. Any future development of Gencaro, including initiating any Phase 3 clinical trial, is dependent on obtaining significant additional financing, even if we enter into a strategic collaboration around the development of Gencaro.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13723541&RcvdDate=11/6/2019&CoName=ARCA%20BIOPHARMA%2C%20INC.&FormType=10-Q&View=html
Sure sounds like the insiders are telling the outsiders to wait???
* * $ABIO Video Chart 09-11-2019 * *
Link to Video - click here to watch the technical chart video
So what is wrong with this?? Anyone??
* * $ABIO Video Chart 06-03-2019 * *
Link to Video - click here to watch the technical chart video
$ABIO Thinking about buying stock in Arca Biopharma, Cronos Group, Nio Inc., Precipio, or Square?
https://www.thechestnutpost.com/news/thinking-about-buying-stock-in-arca-biopharma-cronos-group-nio-inc-precipio-or-square/
Followers
|
105
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2420
|
Created
|
12/11/06
|
Type
|
Free
|
Moderators |
***These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
The Science:
GENETIC-AF Clinical Trial
GENETIC-AF is planned as a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to metoprolol CR/XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then, depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients.
Under the collaboration with Medtronic, ARCA plans to conduct a substudy that will include continuous monitoring of the cardiac rhythms of all 200 patients enrolled during the Phase 2B portion of GENETIC-AF. Each patient will have heart rhythm monitoring via a Medtronic device, either a previously implanted cardiac resynchronization or defibrillation device, or a previously or newly inserted Reveal® loop recorder. The collaboration substudy will measure AF burden, defined as a patient’s actual time in AF regardless of symptoms. For the DSMB interim analysis, AF burden and the primary endpoint of the study, time to recurrence of symptomatic AF after electrical cardioversion, or death, will be reviewed by the DSMB to determine if there is sufficient potential for a statistically significant efficacy signal to be determined for all patients enrolled in the Phase 2B/3 study.
Gencaro Data in Atrial Fibrillation
Clinical data analysis from a post-hoc review of patient forms from the from BEST trial, a Phase 3 trial in 2,708 patients with advanced heart failure, indicate that Gencaro may have a potentially enhanced and pharmacogenetically-influenced effect in reducing and preventing AF. In that trial, patients in the Gencaro arm had a reduction in the risk of new onset AF time to event compared to patients in the placebo arm of 41% (AF measured as an adverse event/serious adverse event or as detected on surveillance ECGs, time to event analysis, p = 0.0004). In a 1,040 patient DNA substudy of BEST, Gencaro exhibited potential pharmacogenetic enhancement and differentiation for AF prevention in patients with a specific genotype (beta1389 arginine homozygous (Arg/Arg) adrenergic receptor (AR); approximately 47% of the patients). These patients experienced a 74% (p = 0.0003) reduction in risk of AF versus no detectable reduction in patients who had alternative genotypes (beta1389 Gly carriers; 53% of the patients) who had received placebo. The Company believes this data supports the potential ability of Gencaro to prevent AF in patients who have the genotype the Company believes responds most favorably to Gencaro.
In prior placebo controlled trials of beta blockers in chronic HFREF, most studies comparing beta-blockers to placebo have detected a positive signal for prevention of AF, with an event rate reduction averaging approximately 27%, although AF had not been a pre-specified primary or secondary endpoint in these studies. Currently, no beta-blocker has been approved by the U.S. Food and Drug Administration for the prevention of
AF in heart failure patients.
Gencaro™ [Bucindolol Hydrochloride]
ARCA is currently developing Gencaro™ (tradename pending FDA approval) (bucindolol hydrochloride) for the prevention of atrial fibrillation and the treatment of chronic heart failure. Gencaro™ is a pharmacologically unique beta-blocker and mild vasodilator. Gencaro™ is considered part of the beta-blocker class because of its property of blocking beta-1 as well as beta-2 receptors in the heart, preventing these receptors from binding with other molecules that would otherwise activate the receptor. Because of its mild vasodilator effects, the Company believes Gencaro™ is well-tolerated in patients with advanced HF. ARCA has identified common genetic variations, or genetic markers, that it believes predict patient response to Gencaro™.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |